Evidence map›Paper›PMID 39310755›Full record

ArticleiScience2024

Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models.

Daniel E Tsai, Alexei Lovanov, Abdalla Abdelmaksoud, Jawad Akhtar, Mohd Saleem Dar, Marie Luff, Katherine McKinnon, Sohyoung Kim, Yvette Robbins, Angel Huynh and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Daniel E TsaiThoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Alexei LovanovCollaborative Bioinformatics Resource (CCBR), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD 20892, USA.
Abdalla AbdelmaksoudCollaborative Bioinformatics Resource (CCBR), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD 20892, USA.
Jawad AkhtarThoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Mohd Saleem DarThoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Marie LuffThoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Katherine McKinnonCenter for Cancer Research Vaccine Branch Flow Cytometry Core, National Cancer Institute, Bethesda, MD 20892, USA.
Sohyoung KimLaboratory of Receptor Biology and Gene Expression, National Cancer Institute, Bethesda, MD 20852, USA.
Yvette RobbinsHead and Neck Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20852, USA.
Angel HuynhHead and Neck Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20852, USA.
Madhavi MuraliThoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Benjamin BernardThoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Andrew SinkoeCenter for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20852, USA.
Xiaolin LuoIonis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA.
Karim BMolecular Histopathology Laboratory, National Institutes of Health, Frederick, MD 21702, USA.
Clint T AllenHead and Neck Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20852, USA.
Vassiliki SalouraThoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

SET and MYND-domain containing protein 3 (SMYD3) mediates epigenetic repression of type I IFN response genes in human papillomavirus (HPV)-negative HNSCC cells, and Smyd3 depletion using anti-sense oligonucleotides (ASOs) increases the sensitivity of syngeneic mouse oral carcinoma (MOC1) models to anti-PD-1 therapy. In this study, we utilized single-cell RNA-seq of MOC1 tumors treated with Smyd3 ASOs and found enrichment of type I IFN response pathways in cancer cells, a shift of CD8

Indexed as

Cell biologyImmunologyMicroenvironment

Identifiers

PMID39310755
PMCPMC11416682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.